Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study

Introduction: The approval of extended half-life recombinant factor IX (rFIX) replacement products has expanded the range of therapeutic options available for the treatment of hemophilia B. Compared with standard half-life FIX, these products allow for extended dosing intervals while maintaining app...

Full description

Bibliographic Details

Published in:	Blood Vol. 138; no. Supplement 1; p. 1039
Main Authors:	Journeycake, Janna, Cheng, Dunlei, Chrisentery-Singleton, Tammuella, Desai, Vidhi, von Drygalski, Annette, Fedor, Carol, Hirsh, Nikki, Patel, Birju, Raffini, Leslie J., Recht, Michael, Sidinio, Robert F., Wang, Michael, Zhang, Xiang, Neufeld, Ellis J.
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 23-11-2021
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!